10 April 2024 - NICE has published final evidence-based recommendations on the use of cabozantinib maleate (Cabometyx) in combination with nivolumab (Opdivo) for the first-line treatment of adults with advanced renal cell carcinoma.

Cabozantinib maleate, when used in combination with nivolumab, is recommended as an option for the first-line treatment of adults with advanced renal cell carcinoma only if:

• Their disease is intermediate or poor risk as defined in the International Metastatic Renal Cell Carcinoma Database Consortium criteria
• The combination of nivolumab and ipilimumab or lenvatinib mesylate and pembrolizumab would otherwise be offered
• The companies provide cabozantinib maleate and nivolumab according to their commercial arrangements

Read NICE technology appraisal guidance